DDD Partners LLC Cuts Stock Position in AbbVie Inc. $ABBV

DDD Partners LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 17.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,406 shares of the company’s stock after selling 18,274 shares during the quarter. AbbVie accounts for approximately 1.3% of DDD Partners LLC’s investment portfolio, making the stock its 16th biggest position. DDD Partners LLC’s holdings in AbbVie were worth $20,469,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. WJ Financial Advisors LLC acquired a new position in shares of AbbVie in the third quarter worth $557,000. Omnia Family Wealth LLC raised its stake in shares of AbbVie by 12.7% in the third quarter. Omnia Family Wealth LLC now owns 5,042 shares of the company’s stock valued at $1,167,000 after acquiring an additional 570 shares in the last quarter. New World Advisors LLC boosted its holdings in AbbVie by 12.6% in the third quarter. New World Advisors LLC now owns 1,837 shares of the company’s stock valued at $425,000 after purchasing an additional 205 shares during the period. Naviter Wealth LLC grew its stake in AbbVie by 4.7% during the 3rd quarter. Naviter Wealth LLC now owns 19,735 shares of the company’s stock worth $4,570,000 after purchasing an additional 885 shares in the last quarter. Finally, Long Island Wealth Management Inc. acquired a new position in AbbVie during the 3rd quarter worth $242,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Guggenheim raised their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Stock Up 1.8%

Shares of ABBV opened at $231.57 on Friday. The company has a market capitalization of $409.28 billion, a price-to-earnings ratio of 98.12, a price-to-earnings-growth ratio of 0.79 and a beta of 0.35. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a 50 day moving average price of $223.56 and a 200 day moving average price of $220.64.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.